These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 25636427)
21. Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos. Shackney SE; Shankey TV Cytometry; 1995 Sep; 21(1):2-5. PubMed ID: 8529466 [TBL] [Abstract][Full Text] [Related]
22. [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques]. Hofman V; Ilie M; Gavric-Tanga V; Lespinet V; Mari M; Lassalle S; Butori C; Coelle C; Bordone O; Selva E; Lamy A; Sabourin JC; Hofman P Ann Pathol; 2010 Apr; 30(2):85-93. PubMed ID: 20451063 [TBL] [Abstract][Full Text] [Related]
23. Cancer. Cancer cell phenotypes, in fifty shades of grey. Marusyk A; Polyak K Science; 2013 Feb; 339(6119):528-9. PubMed ID: 23372002 [No Abstract] [Full Text] [Related]
25. Intratumor diversity and clonal evolution in cancer--a skeptical standpoint. Gisselsson D Adv Cancer Res; 2011; 112():1-9. PubMed ID: 21925299 [TBL] [Abstract][Full Text] [Related]
26. Bone Marrow work-up: report of a pilot study. Anagnostopoulos I; Lenze D; Hummel M; Dietel M; Jöhrens K Recent Results Cancer Res; 2015; 199():95-105. PubMed ID: 25636433 [TBL] [Abstract][Full Text] [Related]
27. Clonal heterogeneity of tumor may be due to continuous influx of newly transformed cells. Lichtenstein AV Cancer Biol Ther; 2006 Oct; 5(10):1263-4. PubMed ID: 17012833 [No Abstract] [Full Text] [Related]
28. Cancer epigenetics as biomarkers of clinical significance. Panayiotidis MI Cancer Lett; 2014 Jan; 342(2):168-9. PubMed ID: 24183850 [No Abstract] [Full Text] [Related]
29. Cancer: an epigenetic landscape. Dhanasekaran K; Arif M; Kundu TK Subcell Biochem; 2013; 61():399-417. PubMed ID: 23150260 [No Abstract] [Full Text] [Related]
30. Tumor clonality: research and clinical aspects. Nemtsova MV; Kushlinskii NE Bull Exp Biol Med; 2014 Dec; 158(2):246-51. PubMed ID: 25432282 [TBL] [Abstract][Full Text] [Related]
31. [Guidelines for hospital molecular genetics platforms of cancers.Institut National du Cancer]. Working Group of the Institut National du Cancer Ann Pathol; 2011 Jun; 31(3):135-7. PubMed ID: 21736991 [No Abstract] [Full Text] [Related]
32. [Towards a standardization of the tools for the studies of clinical proteomics]. Lucchi G; Hendra JB; Pecqueur D; Ducoroy P Med Sci (Paris); 2007 Mar; 23 Spec No 1():19-22. PubMed ID: 17669348 [TBL] [Abstract][Full Text] [Related]
34. [Tools and procedures in the management of surgical specimens]. Discepoli S Suppl Tumori; 2002; 1(3):S95. PubMed ID: 12415800 [No Abstract] [Full Text] [Related]
35. Pre-analytics and tumor heterogeneity. Bonin S; Stanta G N Biotechnol; 2020 Mar; 55():30-35. PubMed ID: 31580921 [TBL] [Abstract][Full Text] [Related]
36. Commentary: Frailty and heterogeneity in epidemiological studies. Moolgavkar SH Int J Epidemiol; 2015 Aug; 44(4):1425-6. PubMed ID: 25878216 [No Abstract] [Full Text] [Related]
37. Failure of fidelity of vertical transmission of epigenetic patterning as the basis of cancer. Riley PA Melanoma Res; 2014 Oct; 24(5):424-7. PubMed ID: 25185692 [No Abstract] [Full Text] [Related]
38. The challenges posed by cancer heterogeneity. Bhatia S; Frangioni JV; Hoffman RM; Iafrate AJ; Polyak K Nat Biotechnol; 2012 Jul; 30(7):604-10. PubMed ID: 22781679 [No Abstract] [Full Text] [Related]